According to a report conducted by the New England Healthcare Institute (NEHI), poor medication adherence is a pervasive problem that costs $290 billion a year in the U.S. Forgetting to take medication and not understanding administration instructions are among the main reasons why between 20 and 50 percent of patients are not adhering to their medical regimens. Smart drug systems like Smart Patches will increase globally to nearly $81.4 billion by 2024 as they provide a more targeted, uniform and secure method of drug delivery.
"Poor medical adherence negatively impacts patients’ therapeutic outcomes, leading to more hospitalizations and higher total costs," said Dr. Hanshermann Franke, Corp. VP of R&D at LTS. "The main purpose of any innovation must be centered on the idea of making patients’ lives as healthy and comfortable as possible. This can be achieved by designing "smart" solutions that easily integrate, facilitate treatment monitoring and help patients use their medication properly."
The Smart Patch is equipped with a 2” E Ink electronic paper display (EPD) that leverages the display’s bistable nature to ensure the patient doesn’t need to recharge the battery. The patch features a switch, pressure sensor and a low voltage E Ink display that shows helpful information with functionalities including:
- A message indicating whether the patch is applied correctly to the skin
- A countdown until the next dose
- A reminder to remove the patch and to replace it appropriately
"This is the first application to feature E Ink’s low voltage film, which uses 50-70 percent of the typical driving voltage for EPDs," said Dr. FY Gan, EVP of Sales Center at E Ink. "In addition to minimizing power consumption, which results in the ability to use a small battery with a longer battery life, the low voltage film is the thinnest electronic paper film available on the market at less than 200um, enabling it to fit flawlessly on the TTS."
"There are many advantages to TTS technologies, and now we can add a decisive enhancement - an E Ink display," said Dr. Tim Schlange, CMO at LTS. "This feature allows LTS to provide functionalities to patients with more reliable, safe and pain-free applications and to further enhance the value of solutions for its partners in the pharmaceutical industry."
"Medical innovation is happening at an unprecedented rate and we are excited to partner with a company that is providing unique drug delivery systems in the marketplace to improve medical compliance," said Dr. Paul Apen, Chief Strategy Officer at E Ink. "Our displays are a natural fit for this type of drug delivery system as they are thin, have a wide viewing angle and consume minimal power for continued use. This is just one of the ways our display technology is impacting the future of medical applications."
The Smart Patch concept will initially target the treatment of chronic diseases. The first prototype will be displayed during CPhI in Messe Frankfurt, Germany October 24-26, 2017 at LTS's booth 4.0 C40.
About E Ink Holdings
E Ink Holdings Inc. (8069.TWO), based on technology from MIT’s Media Lab, has transformed and defined the eReader market and is redefining the signage, architecture and design, mobile, wearable and retail markets with its ePaper technology, enabling a new multi-billion dollar market in less than 10 years. Its corporate philosophy aims to deliver revolutionary products, user experiences and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications including smart packaging and fashion. Its Electrophoretic Display products make it the worldwide leader for ePaper. Its Fringe Field Switching (FFS) technologies are a standard for high-end LCD displays and have been licensed to all major liquid crystal display makers in the world. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of ePaper displays.
About LTS Lohmann Therapie Systeme AG
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS") and Oral Thin Films ("OTF") for the pharmaceutical industry. LTS's innovation model consists of both partner-funded and self-funded initiatives currently encompassing more than 20 marketed products and a deep and diverse pipeline of development projects targeting multiple disease indications. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.